3 years 0.01
Extreme 0.008
0.96
5 years 0.01
Extreme 0.008
4.72
10 years 0.01
Extreme 0.008
15.41
Manager TitleAgeSince
Chief Executive Officer 55 -
Chief Tech/Sci/R&D Officer - 01/06/2021
Chief Operating Officer 59 24/05/2024
Director TitleAgeSince
Chairman 55 -
Director/Board Member 56 01/04/2019
Date Insider Type Main position Quantity % Market Cap. Importance
31/01/24 Free

Chief Technology Officer

4,80,319 0.3621%
31/01/24 Free

Director

2,00,000 0.1508%
31/01/24 Free

Director

2,00,000 0.1508%
Change 5-day change 1-year change 3-year change Capi.($)
+2.41%-.--% - - 26.19L
+0.65%-3.56%+33.53%+60.50% 6.35TCr
+1.76%+2.10%+12.10%+81.21% 5.45TCr
-0.94%+0.77%+8.85%+100.19% 5.36TCr
+2.76%+4.18%+28.34%+55.07% 4.48TCr
+2.00%-2.90%+18.37%+119.04% 4.16TCr
+1.34%-3.98%+225.44%+914.08% 3.99TCr
+0.64%-3.85%+11.71%+45.57% 3.25TCr
+29.06%+48.65%+106.84%+92.73% 2.67TCr
+3.72%-7.45%+24.25%-2.99% 2.34TCr
Average +4.34%-0.42%+52.16%+162.82% 4.23TCr
Weighted average by Cap. +3.23%-0.29%+47.56%+161.47%
Logo Gamida Cell Ltd.
Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and potency. The Company's clinical pipeline products include: Omidubicel dedicated to hematologic malignancies and severe aplastic anemia; GDA-201 dedicated for treatment of non-Hodgkin Lymphoma; GDA-301, GDA-401, GDA-501 dedicated to treatment of solid tumors, GDA-601 dedicated to multiple myeloma.
Employees
147
  1. Stock Market
  2. Stocks
  3. GMDA Stock